Search - tctmd.com

Displaying 1 - 20 of 32

Sort: Relevancy | Date

News Opinion Editor's Corner ACC 2025

What’s Going to Be Hot at ACC 2025?

Michael O'Riordan

March 26, 2025

News Conference News ACC 2024

PREVENT Supports Early PCI for Vulnerable Plaque, With Reductions in MACE

L.A. McKeown

April 08, 2024

$Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC$

News Conference News ACC 2024

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Michael O'Riordan

April 08, 2024

$Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)$

Presentation ACC 2024

Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)

Presenter: Rasha K. Al-Lamee

April 08, 2024

News Conference News ACC 2024

Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT

Todd Neale

March 27, 2024

News Conference News ACC 2023

AIMI-HF Misses Mark With Advanced Imaging in Ischemic HFrEF Workup

L.A. McKeown

March 09, 2023

News Conference News ACC 2023

No Downside to Immediate Complete Revascularization in ACS: BIOVASC

Michael O'Riordan

March 06, 2023

News Conference News ACC 2022

No Difference in 1-Year QoL Between FFR-Guided PCI and CABG: FAME-3

Michael O'Riordan

April 13, 2022

News Conference News ACC 2022

FLAVOUR: FFR as Good as IVUS for Intermediate Coronary Stenoses

Michael O'Riordan

April 06, 2022

News Conference News ACC 2022

Better Angina Relief With Complete PCI in STEMI and MVD

L.A. McKeown

April 02, 2022

News Conference News ACC 2021

Complete Revascularization Analysis of ISCHEMIA Opens ‘Pandora’s Box’

Michael O'Riordan

May 18, 2021

News Conference News ACC 2020

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

Todd Neale

April 02, 2020

News Conference News ACC 2020

Ischemia Burden Not Linked to Angina in Nonobstructive CAD: CIAO

Michael O'Riordan

March 31, 2020

News Conference News ACC 2020

ISCHEMIA in Print: New MI Data and More Calls for Longer Follow-up

Shelley Wood

March 30, 2020

News Conference News ACC 2019

REDUCE-IT Subanalysis: Icosapent Ethyl Reduces Total and Recurrent CV Events

Yael L. Maxwell

March 22, 2019

News Conference News ACC 2019

Modest LDL Cholesterol Reduction With Bempedoic Acid in Among High-Risk Patients: CLEAR Wisdom

Michael O'Riordan

March 20, 2019

News Conference News ACC 2018

High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab

Michael O'Riordan

March 20, 2018

News Conference News ACC 2018

Precision Medicine Gamble Fails for CETP Inhibitors in ACCELERATE Analysis

Michael O'Riordan

March 14, 2018

News Conference News ACC 2018

Gout Drug Febuxostat Linked to More CV Deaths Without Uptick in CV Events: CARES Trial

Caitlin E. Cox

March 14, 2018

News Conference News ACC 2018

Canakinumab Falls Short of Halting Progression to Diabetes in Patients at Risk: CANTOS

Michael O'Riordan

March 12, 2018

Advertisement

What’s Going to Be Hot at ACC 2025?

PREVENT Supports Early PCI for Vulnerable Plaque, With Reductions in MACE

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)

Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT

AIMI-HF Misses Mark With Advanced Imaging in Ischemic HFrEF Workup

No Downside to Immediate Complete Revascularization in ACS: BIOVASC

No Difference in 1-Year QoL Between FFR-Guided PCI and CABG: FAME-3

FLAVOUR: FFR as Good as IVUS for Intermediate Coronary Stenoses

Better Angina Relief With Complete PCI in STEMI and MVD

Complete Revascularization Analysis of ISCHEMIA Opens ‘Pandora’s Box’

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

Ischemia Burden Not Linked to Angina in Nonobstructive CAD: CIAO

ISCHEMIA in Print: New MI Data and More Calls for Longer Follow-up

REDUCE-IT Subanalysis: Icosapent Ethyl Reduces Total and Recurrent CV Events

Modest LDL Cholesterol Reduction With Bempedoic Acid in Among High-Risk Patients: CLEAR Wisdom

High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab

Precision Medicine Gamble Fails for CETP Inhibitors in ACCELERATE Analysis

Gout Drug Febuxostat Linked to More CV Deaths Without Uptick in CV Events: CARES Trial

Canakinumab Falls Short of Halting Progression to Diabetes in Patients at Risk: CANTOS

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content